Vitamin D: when to test, when to treat, and what has not been demonstrated
25-hydroxyvitamin D is the correct blood marker for vitamin D status. But routine testing and high-dose supplementation for every healthy adult are not supported by current evidence.
The quick answer
Measure 25(OH)D when the result answers a defined clinical question—not because more testing feels preventive.
Serum 25-hydroxyvitamin D integrates skin production, food, and supplements and is the preferred status marker. The 2024 Endocrine Society guideline suggests against routine 25(OH)D testing in generally healthy populations studied, while targeted measurement remains appropriate when deficiency, altered metabolism, bone disease, malabsorption, or treatment monitoring is clinically plausible.
25(OH)D is the status test
It is the main circulating form and best reflects vitamin D exposure from skin, food, and supplements.
1,25(OH)₂D answers another question
The active hormone can be normal or high in deficiency and is reserved for selected renal, calcium, parathyroid, and granulomatous questions.
A target is not universal
Thresholds differ by organization, population, outcome, and assay. A laboratory flag is not automatically a treatment mandate.
The central ruleVitamin D should be tested and treated for a reason. A higher number is not automatically a better health outcome.
Side by side
Four measurements that are often confused.
Reading the result
The same concentration can lead to a different decision.
Intervals are not universal. Interpret the assay, units, clinical indication, calcium–PTH context, and treatment exposure.
Low by major Brazilian and U.S. frameworks
Supports deficiency or inadequacy depending on the framework and clinical context; investigate cause and consequence rather than assuming one dose fits all.
The disputed middle zone
NIH/National Academies generally regards 20 ng/mL as adequate for most people; Brazilian guidance seeks 30–60 ng/mL in selected higher-risk groups.
Often used for higher-risk Brazilian groups
A range used in the SBEM/SBPC/ML position for selected risk conditions—not proof that every healthy person benefits from targeting it.
No routine reason to chase higher
Potential adverse effects become more concerning as concentrations rise; toxicity is classically associated with excessive supplement exposure and hypercalcemia.
MERHI ONE Evidence Map
What is established, uncertain, and unsupported.
The rating applies to each exact use of testing or supplementation.
Serum 25(OH)D is the preferred laboratory marker of vitamin D status.3,4,5,6
It reflects cutaneous synthesis, dietary intake, and supplements better than the tightly regulated active hormone.
Routine 25(OH)D testing is not recommended for generally healthy adults without an established indication.1,2
The Endocrine Society suggests against routine testing in the populations it reviewed, and the USPSTF finds insufficient evidence to recommend population screening in asymptomatic community-dwelling nonpregnant adults.
Testing is clinically useful when deficiency or altered vitamin D metabolism could change management.3,4,6
Examples include suspected osteomalacia, selected osteoporosis pathways, malabsorption or bariatric surgery, chronic kidney or liver disease, hyperparathyroidism, relevant medications, and monitoring of a defined replacement plan.
There is one universally proven ‘optimal’ 25(OH)D concentration for all outcomes and all adults.1,2,3,4
Organizations use different thresholds, and trial evidence does not establish a single concentration that optimizes skeletal, cardiovascular, cancer, metabolic, immune, and cognitive outcomes simultaneously.
1,25(OH)₂D should not be used as a routine screening test for deficiency.3,6
Renal and parathyroid regulation can maintain or increase the active hormone even when 25(OH)D stores are low.
Testing and supplementing every healthy adult to a high target prevents cancer, cardiovascular disease, diabetes, depression, or dementia.1,2,3
Observational associations do not establish that raising the biomarker changes these outcomes, and current prevention guidelines do not support universal target-based testing.
High-dose or intermittent megadose vitamin D is harmless because it is a vitamin.1,3,4
Excess exposure can cause hypercalcemia, hypercalciuria, kidney stones, kidney injury, arrhythmia, and soft-tissue calcification; some bolus regimens have not improved outcomes and may increase falls.
Two native pathways
The test is the same; thresholds and screening language differ.
United States — Endocrine Society / USPSTF / NIH
- The 2024 Endocrine Society guideline suggests against routine testing in generally healthy groups studied.
- USPSTF evidence is insufficient for screening asymptomatic nonpregnant community-dwelling adults.
- NIH/National Academies generally regards 20 ng/mL as adequate for most people and cautions against persistently high levels.
Brazil — SBEM / SBPC/ML
- The 2020 position describes below 20 ng/mL as deficient and 20–60 ng/mL as normal for the general population.
- For selected higher-risk groups, 30–60 ng/mL is presented as a desirable range.
- Brazilian guidance emphasizes assay limitations and targeted testing rather than interpreting one concentration without clinical context.
When measurement is more useful
Pretest probability and consequences determine value.
Bone pain, fractures, low bone density, or muscle weakness
Testing may contribute when osteomalacia or a bone-mineral disorder is plausible.
Malabsorption or bariatric surgery
Reduced absorption can justify baseline and follow-up testing through a defined pathway.
Chronic kidney or liver disease
Metabolism and mineral physiology change; companion calcium, phosphate, PTH, and kidney data may be needed.
Hyperparathyroidism or abnormal calcium
25(OH)D helps interpret the calcium–PTH axis, while 1,25(OH)₂D is reserved for selected questions.
Medications affecting bone or vitamin D metabolism
Anticonvulsants, glucocorticoids, and some other therapies can change the indication and monitoring plan.
Already taking high doses
Measurement may be needed to assess efficacy or toxicity, alongside calcium and renal context.
Common interpretation errors
Vitamin D is vulnerable to ‘optimal range’ marketing.
The main risks are unnecessary testing, overtreatment, and promises unsupported by clinical outcomes.
‘Everyone must be above 30 or 40 ng/mL’
No universal outcome-based target exists for every healthy adult.
‘1,25(OH)₂D is the best status test’
It is tightly regulated and can mislead in deficiency.
‘Low vitamin D explains every symptom’
Fatigue, pain, mood, and hair complaints have broad differentials.
‘More vitamin D means more immunity’
Dose–response is not unlimited and broad prevention benefit is unproven.
‘A normal result proves supplements are necessary forever’
Ongoing need depends on cause, exposure, diet, disease, and plan.
‘Toxicity is impossible’
Excess supplements can cause clinically important hypercalcemia and kidney injury.
Possible consequences of overtesting or overtreatment
- Hypercalcemia and hypercalciuria
- Kidney stones or kidney injury
- Unnecessary recurring laboratory cost
- Missed alternative cause of symptoms
- False disease labeling
- Drug and supplement interaction
A practical next step
Define the reason before the target.
- 01
Ask whether this is screening, diagnosis, risk assessment, or monitoring.
- 02
If testing is indicated, use 25(OH)D and record the assay units and reference framework.
- 03
Review calcium, kidney function, PTH, absorption, medications, supplements, diet, and relevant bone history when appropriate.
- 04
Treat the clinical condition and cause, not an internet target.
- 05
Avoid long-term high-dose therapy without a defined indication and safety plan.
Frequently asked questions
Direct answers to practical questions.
Should everyone test vitamin D every year?+
No. Current evidence does not support routine annual testing of every healthy adult.
Which test should I order?+
25-hydroxyvitamin D, written as 25(OH)D, is the standard status test.
Is 20 or 30 ng/mL the correct cutoff?+
It depends on the guideline and risk group. NIH/National Academies and Brazilian specialty guidance use different contextual thresholds.
Does vitamin D prevent cancer or heart disease?+
Universal target-based testing and supplementation have not demonstrated broad prevention of these outcomes.
Can high doses be dangerous?+
Yes. Excess can cause high calcium, kidney stones, kidney injury, arrhythmia, and calcification.
When should 1,25(OH)₂D be measured?+
Only for selected kidney, calcium, parathyroid, granulomatous, or rare metabolic questions—not routine status screening.
Scientific sources
References are part of the reasoning—not decoration.
We prioritize current guidelines, public-health recommendations, official nutrient references, and laboratory-method standards.
- 01Open source ↗
Endocrine Society · 2024
Vitamin D for the Prevention of Disease: Clinical Practice Guideline
- 02Open source ↗
U.S. Preventive Services Task Force · 2021
Vitamin D Deficiency in Adults: Screening
- 03Open source ↗
NIH Office of Dietary Supplements · Updated 2025
Vitamin D: Fact Sheet for Health Professionals
- 04Open source ↗
SBEM / SBPC/ML · 2020
Reference Values of 25-Hydroxyvitamin D Revisited
- 05Open source ↗
NIH Office of Dietary Supplements · Methods resource
Vitamin D Biomarkers Methods Workshop
- 06Open source ↗
SBEM · 2014
Brazilian Recommendations for the Diagnosis and Treatment of Hypovitaminosis D
Editorial record